The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic ...
Schmid detailed the rationale of combining pumitamig and chemotherapy and how the combination can aid patients in the first ...
Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...
PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback